USE OF SET7/9 FOR DIAGNOSING AND TREATING ENDMT-RELATED DISEASE

The present invention relates to a use of SET7/9 for diagnosing and treating an endothelial-mesenchymal transition (EndMT)-related disease, and the present inventors have confirmed that a simultaneous treatment of TGF-β2 and IL-1β is a strong inducing condition for endothelial-mesenchymal transition...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YUN, Eunsik, LEE, Aram, KOOK, Yunjin, KIM, Jongmin
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a use of SET7/9 for diagnosing and treating an endothelial-mesenchymal transition (EndMT)-related disease, and the present inventors have confirmed that a simultaneous treatment of TGF-β2 and IL-1β is a strong inducing condition for endothelial-mesenchymal transition, methyltransferase SET7/9 is an important epigenetic factor in a process of inducing endothelial-mesenchymal transition, and SET7/9 inhibition regulates pro-fibrotic signaling and inhibits endothelial-mesenchymal transition. In addition, it was found that a vascular endothelial cell dysfunction caused by endothelial-mesenchymal transition was restored by the SET7/9 inhibition and the endothelial-mesenchymal transition was closely related to a pulmonary vascular disease.